McGill University Oncology II
TACKLING ONCOLOGY OUR GOAL:
- There have been a number of exciting breakthroughs and advancements in the diagnosis, treatment and care of oncology patients.
- Estimated 1300 “oncology” compounds in various places with the drug development pipeline.
- Explosion of molecules coming to market over the next decade.
- Primary Care Physicians will be more involved with the management of Oncology patients.
- The industry will be requiring the redeployment of representatives into the oncology milieu.
This program and McGill University Oncology II are required to receive Oncology certification from CCPE. Please click here to go to the Oncology I page. You can choose to register for both McGill University Oncology I & II at the same time, however McGill University Oncology I is a prerequisite to II.
This course is administered entirely on-line. Course content and exams are all delivered by the CCPE Learning Management System. (Previous CCPE students will recognize use of the LMS from taking their online exams.)
Students will need to successfully complete both Oncology I and Oncology II to be certified in Oncology (the completion of both programs is required for CCPE awards and medals).
After completing the course, students will be able to:
- Discuss the epidemiology, detection, diagnosis, and treatment of various types of cancer
- 8 individual Multiple Choice / Case based module mini-exams (totaling 76 multiple-choice questions) are taken after each individual learning module for increased efficiency and reduced stress.
- Mini exams are each 12 minutes to 60 minutes per module.
- A weighted average of 55% on 8 mini exams is required to pass the course. (You can fail individual exams and still pass the course as a whole.)
- 6 months to complete the entire course
- Suggested Hours of Study 49
- Quizzes 0
- Suggested Hours of Study 30 hours
- Course Completion 6 months
- Course Format E-Learning
- RxTx Yes
- Language English
- Pages 8 e-modules
- C.E. Credits What is this? 3
- Orientation Package
- # of Questions 76
- Time Limit 12 - 60 min. / module
- Passing Grade 55%
- Price $904.00
- Corporate Member $452.00
- Corporate Non-Member $2,260.00
Module 10 - Prostate Cancer
Prostate cancer is the most frequently diagnosed non-cutaneous adult male malignancy. This module will discuss the symptoms and risks factors associated with the disease, the pros and cons of screening, the patients' stratification process, and the prognosis and treatment of prostate cancer. After reading this module, you should be able to:
- 1. Identify the risk factors for the development of prostate cancer.
- 2. Stratify patients based on risk for prostate cancer.
- 3. Describe the pros and cons of screening for prostate cancer.
- 4. Describe the signs and symptoms of prostate cancer.
- 5. Describe the prognosis and treatment of prostate cancer.
Module 11 - Bladder & Kidney Cancers
In Canada, bladder and kidney cancers are the sixth and ninth most common cancers respectively. This module discusses the etiology and risk factors associated with the diseases, as well as advances in the diagnosis and treatment of bladder and kidney cancers. After reading this module, you should be able to:
Module 12 - Skin Cancer & Sarcoma
The skin can be considered to be the largest organ in the body. During a person’s lifetime, the risk of developing cancer of the skin approaches 20%. Approximately 97% of skin cancers are non-melanoma skin cancers. Melanoma represents approximately 4% of skin cancers and sarcomas about 1% of all cancers. After reading this module you should be able to:
- 1. Explain why skin cancer has the highest incidence of all cancer types.
- 2. Describe the two main sub-types of non-melanoma skin cancer.
- 3. Explain the importance of early diagnosis of malignant melanoma.
- 4. Understand the difference between soft tissue sarcoma and bone sarcoma.
- 5. Appreciate the importance of early and complete surgical resection of malignant melanoma.
- 6. Explain the importance of combination therapy for different types of sarcomas.
Module 13 - Gynecological Cancers
In developing countries where human papillomavirus (HPV) screening is not available, cervical cancer is the most common cancer of the female genital tract and the second most common cancer among women in general. In Canada, the most common malignancy of the female genital tract, accounting for 6% of all cancers in women, is endometrial cancer. The leading cause of death due to gynecological cancers among women in developed countries is ovarian cancer, due to the fact that 75% of ovarian cancers are diagnosed at advanced stages. After reading this module, you should be able to:
- 1. Describe the etiology and risk factors for the development of endometrial and cervical cancer.
- 2. Describe the challenges and methods in the diagnosis and screening of cervical, endometrial and ovarian cancers.
- 3. Identify the signs and symptoms of cervical, endometrial and ovarian cancers.
- 4. Describe the staging of the cancers.
- 5. Describe the prognosis, treatment and follow up procedures for cervical, endometrial and ovarian cancers.
Module 14 - Pancreas and Liver Cancers
The liver and pancreas are two large exocrine and endocrine organs of the body. They are located in close proximity to each other. Cancers of these organs are highly malignant and affect functioning of the whole organism early on. The liver is also one of the most common organs for metastatic disease from primary cancers of other tissues and organs. After reading this module, you should be able to:
- 1. Differentiate the types of pancreatic cancer and distinguish the major types of hepatobiliary cancers.
- 2. Describe the etiology, risk factors, and recommended screening guidelines for pancreatic and liver cancers.
- 3. Identify the primary tumors that commonly metastasize to the liver.
- 4. Discuss patient presentation and diagnostic tests for pancreatic and liver cancers.
- 5. Explain the histopathology and staging of pancreatic and liver cancers.
- 6. Describe treatment strategies for pancreatic cancer and liver cancers.
Module 15 - Neoplasms of the Central Nervous System
Tumors of the central nervous system (CNS) may be either primary or secondary. Primary CNS tumors originate from different tissues of the brain or spinal cord. Together they account for fewer than 2% of all tumors and 2.3% of cancer-related deaths. Secondary brain tumors are metastases from tumors of other organs and tissues. Brain tumors remain very difficult to treat in spite of advances in chemotherapy, surgical treatments, radio-oncological treatments, and increased understanding of pathophysiology. A multidisciplinary management approach is required. After reading this module, you should be able to:
- 1. Describe the difference between primary and secondary tumors of the central nervous system.
- 2. Identify the principal primary brain cancer groups.
- 3. Discuss the diagnosis of primary and secondary tumors of the brain.
- 4. Describe the signs and symptoms of primary and secondary tumors of the brain.
- 5. Explain the treatment of primary and secondary tumors of the brain.
Module 16 - Esophageal & Gastric Cancers
The stomach and esophagus are organs of the upper gastrointestinal (GI) tract. The tissues of these organs are exposed to elements in the external environment, namely food, toxins and bacteria. This exposure may facilitate inflammatory processes and the formation of premalignant conditions, which may subsequently lead to the development of cancer. After reading this module, you should be able to:
- 1. List the risk factors for developing gastric cancer.
- 2. Describe the risk factors associated with squamous cell carcinoma and adenocarcinoma of the esophagus.
- 3. Identify the screening tests for gastric cancer.
- 4. Describe the staging and prognosis for gastric cancer.
- 5. Explain the treatment for gastric cancer.
- 6. Discuss diagnostic testing for esophageal cancer.
- 7. Identify the signs and symptoms of esophageal cancer.
- 8. Explain the management of localized and metastatic esophageal cancer.
Module 17 - Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)
Chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) have only recently been recognized as cancers. Both MPN and MDS are clonal disorders arising from a single pluripotent stem cell within the hematopoietic system. These conditions have variable phenotypic expression and variable clinical severity, ranging from mild conditions to rapidly progressing malignant disorders. MPN and MDS are considered two separate groups of diseases, however, there is some overlap between them. After reading this module, you should be able to:
- 1. Explain the etiology and pathogenesis of the common forms of myeloproliferative neoplasms (MPNs).
- 2. Describe the epidemiology and risk factors of myelodysplastic syndromes (MDS).
- 3. Identify the signs and symptoms of MPN and MDS.
- 4. Discuss and list the investigative tests essential for diagnosis of MPN disorders and MDS.
- 5. Explain the differential diagnosis for MPNs.
- 6. Identify the main categories and risk groups of MDS.
- 7. Distinguish the treatment of lower risk and higher risk MDS.
- 8.Distinguish the course and prognosis of different MPN disorders.
- 9. Explain supportive care available for all MDS patients.
- 10. Describe the treatment approaches appropriate for MPN disease stage.